Key result
Recent European guidelines recommend low-molecular-weight heparins for the treatment of acute venous thromboembolism, prevention of recurrence, and prophylaxis in surgical and medical patients.
This review emphasizes the underuse of routine VTE prophylaxis and discusses European guidelines recommending LMWHs for VTE prevention and treatment.
Guideline recommendations for LMWHs contrast with persistent VTE prophylaxis underuse; leaves open questions on effective implementation strategies.
Venous thromboembolism (VTE) is an important cause of avoidable morbidity and mortality. However, routine prophylaxis for at-risk patients is underused. Recent guidelines issued by an international consensus group, including the International Union of Angiology (IUA), recommend use of low-molecular-weight heparins (LMWHs) for the treatment of acute VTE and prevention of recurrence, and for prophylaxis in surgical and medical patients. This review highlights current inadequacies in the provision of thromboprophylaxis, and considers the clinical implications of the European guidelines on the prevention and treatment of VTE.
No takes yet. Share an insight, caveat, or question.
Paolo Prandoni (2008) conducted a review in Venous thromboembolism (VTE). Low-molecular-weight heparins (LMWHs) was evaluated. Recent European guidelines recommend low-molecular-weight heparins for the treatment of acute venous thromboembolism, prevention of recurrence, and prophylaxis in surgical and medical patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: